Patents by Inventor Luhua Lai

Luhua Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240350643
    Abstract: The present invention relates to a protein degradation agent, and a preparation method therefor and a use thereof. The protein degradation agent can degrade various proteins comprising c-Myc protein, and can therefore be used for the prevention and treatment of diseases related to dysregulation of various proteins comprising c-Myc protein, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection-related diseases.
    Type: Application
    Filed: June 21, 2022
    Publication date: October 24, 2024
    Applicant: SUZHOU KINTOR PHARMACEUTICALS, INC.
    Inventors: Youzhi TONG, Zhaohui YANG, Ruo XU, Liandong MA, Luhua LAI
  • Publication number: 20220324884
    Abstract: Provided are a c-Myc protein inhibitor, and a preparation method therefor and use thereof. The c-Myc protein inhibitor selectively inhibits c-Myc protein. Therefore, the inhibitor can be used for prevention and treatment of diseases related to c-Myc protein disorders, such as cancers, cardiovascular and cerebrovascular diseases, diseases related to virus infection.
    Type: Application
    Filed: July 3, 2020
    Publication date: October 13, 2022
    Applicant: SUZHOU KINTOR PHARMACEUTICALS, INC.
    Inventors: Youzhi TONG, Luhua LAI
  • Patent number: 10722489
    Abstract: This application discloses a D-3-phosphoglycerate dehydrogenase allosteric inhibitor and the use thereof. In one class is the benzoyl hydrazine compound for the allosteric site MDL-1 of the enzyme, and the other class is the furan compound for the allosteric site MDL-2 of the enzyme. In vitro enzymatic activity tests, cell viability tests and mouse xenograft model experiments confirm that the two classes of allosteric inhibitors can specifically inhibit the activity of D-3-phosphoglycerate dehydrogenase and delay the growth of cancer cells by reducing the overexpression of the enzyme in cancer cells. Same are used alone or in combination, or in combination with other anti-cancer drugs and can treat, prevent, or inhibit tumor diseases, including breast cancer, colon cancer, melanoma and non-small cell lung cancer.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: July 28, 2020
    Assignee: Peking University
    Inventors: Luhua Lai, Ying Liu, Qian Wang, Pei Liu
  • Publication number: 20200054593
    Abstract: This application discloses a D-3-phosphoglycerate dehydrogenase allosteric inhibitor and the use thereof. In one class is the benzoyl hydrazine compound for the allosteric site MDL-1 of the enzyme, and the other class is the furan compound for the allosteric site MDL-2 of the enzyme. In vitro enzymatic activity tests, cell viability tests and mouse xenograft model experiments confirm that the two classes of allosteric inhibitors can specifically inhibit the activity of D-3-phosphoglycerate dehydrogenase and delay the growth of cancer cells by reducing the overexpression of the enzyme in cancer cells. Same are used alone or in combination, or in combination with other anti-cancer drugs and can treat, prevent, or inhibit tumor diseases, including breast cancer, colon cancer, melanoma and non-small cell lung cancer.
    Type: Application
    Filed: December 30, 2016
    Publication date: February 20, 2020
    Inventors: Luhua Lai, Ying Liu, Qian Wang, Pei Liu
  • Publication number: 20190262303
    Abstract: This application discloses a D-3-phosphoglycerate dehydrogenase allosteric inhibitor and the use thereof. In one class is the benzoyl hydrazine compound for the allosteric site MDL-1 of the enzyme, and the other class is the furan compound for the allosteric site MDL-2 of the enzyme. In vitro enzymatic activity tests, cell viability tests and mouse xenograft model experiments confirm that the two classes of allosteric inhibitors can specifically inhibit the activity of D-3-phosphoglycerate dehydrogenase and delay the growth of cancer cells by reducing the overexpression of the enzyme in cancer cells. Same are used alone or in combination, or in combination with other anti-cancer drugs and can treat, prevent, or inhibit tumor diseases, including breast cancer, colon cancer, melanoma and non-small cell lung cancer.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Inventors: Luhua Lai, Ying Liu, Qian Wang, Pei Liu